Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method

Information

  • Research Project
  • 8265926
  • ApplicationId
    8265926
  • Core Project Number
    R44HL095203
  • Full Project Number
    5R44HL095203-03
  • Serial Number
    095203
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    9/1/2009 - 15 years ago
  • Project End Date
    8/31/2013 - 11 years ago
  • Program Officer Name
    BUXTON, DENIS B
  • Budget Start Date
    3/1/2012 - 12 years ago
  • Budget End Date
    8/31/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    03
  • Suffix
  • Award Notice Date
    2/29/2012 - 12 years ago
Organizations

Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method

DESCRIPTION (provided by applicant): It was recently discovered that the adult human heart contains small numbers of resident cardiac stem cells. These stem cells are incapable of mounting a full-scale repair of the heart following a heart attack (or myocardial infarction). However, when cultivated in the lab and delivered to animals after a myocardial infarction, these cells can initiate repair processes, form new heart muscle and new vessels. Capricor, Inc. has a method to cultivate resident cardiac stem cells which is known as the cardiosphere method. Cardiospheres can be generated starting with only a small cardiac biopsy that can be obtained during an outpatient procedure. The cardiosphere method is being developed for commercialization as an autologous treatment for cardiovascular disease in general. This project aims to make the cardiosphere method faster, cheaper, and simpler. Cell culture techniques will be modified and product equivalence demonstrated by flow cytometry.es will be applied to determine the efficacy of each cell product. This project will also explore the feasibility of product banking, such that a patient could preserve stem cells for a future application. Cells will be subjected to a controlled-rate freeze followed by a thaw process after a period of banking in liquid nitrogen. Measures of viability and potency will be made to identify any detrimental effects. Finally, with a focus on future clinical trials, we will develop assays that will allow us to predict the potency, or efficacy, of a particular patient's sample. Another series of animal studies will be conducted to measure potency in the setting of myocardial infarction, while a series of simple lab potency assays will be developed in parallel as candidate predictors. Cardiosphere-derived stem cells are already being moved toward a Phase I/II clinical safety trial. The specific aims of this project will move Capricor toward its goal of preparing for a Phase II/III clinical efo provide a possible cure for the disease or halt its progression, and to improve the health of the Nation.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    425410
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:425410\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CAPRICOR, INC.
  • Organization Department
  • Organization DUNS
    625221820
  • Organization City
    BEVERLY HILLS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    902112606
  • Organization District
    UNITED STATES